Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TSPO | P30536 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985999 | 0.87 | PIK3CD (0.56) | PIK3CDALDH1A1KDM4EGLATSPO | |
| SCHEMBL10251837 | 0.84 | PIK3CD (0.43) | PIK3CDALDH1A1ATM | |
| Hydrochloric Acid SCHEMBL4174758 | 0.83 | PIK3CD (0.43) | PIK3CDALDH1A1ATM | |
| SCHEMBL10250927 | 0.78 | PIK3CD (0.65) | PIK3CDALDH1A1KDM4EGLATSPO | |
| SCHEMBL1598367 | 0.78 | CTSA (0.38) | PIK3CDALDH1A1KDM4E | |
| SCHEMBL4176627 | 0.78 | PIK3CD (0.68) | PIK3CDALDH1A1GLACYP3A4ATM | |
| SCHEMBL27802815 | 0.78 | PIK3CD (0.45) | PIK3CDALDH1A1KDM4EGLATSPO | |
| SCHEMBL4433317 | 0.77 | PIK3CD (0.47) | PIK3CDALDH1A1GLACYP3A4ATM | |
| SCHEMBL4173842 | 0.77 | PIK3CD (0.47) | PIK3CDALDH1A1GLACYP3A4ATM | |
| SCHEMBL1313288 | 0.75 | KDM4E (0.44) | PIK3CDALDH1A1KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183259-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20110275653-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275653-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885ALDH1A1 3905/4885KDM4E 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.